Supervised pharmacy student led medication review of patients with diabetes in primary care.
| ISRCTN | ISRCTN26445805 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN26445805 |
| Protocol serial number | 9933 |
| Sponsor | NHS South Norfolk CCG |
| Funder | National Institute for Health Research |
- Submission date
- 13/08/2015
- Registration date
- 13/08/2015
- Last edited
- 01/09/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Medication reviews are beneficial to patients by making sure that the medications they are taking and the monitoring of their condition is appropriate, the patient knows how and why they are taking their medication and the medicines are being taken appropriately. Although pharmacists have good drug knowledge and are trained to help patients to take their medicines, research has shown that to regularly provide medication reviews pharmacists need to develop their communication skills and work more closely with medical practices. We believe that pharmacy student experience of undertaking real medication reviews under close supervision in a medical practice and a later related patient consultation is an innovative model which could provide significant patient benefit at relatively small cost. The aim of this study is to identify the potential patient benefits of these medical reviews and to describe it so that its easily repeated across other schools of pharmacy in the UK.
Who can participate?
Participants with type 2 diabetes taking non-insulin antidiabetes medication
What does the study involve?
First of all, a review of previous work is done alongside focus groups with doctors, patients, pharmacists and students. Patients from four medical practices are then recruited and then randomised to one of two groups. Those in group 1 undergo a student led medication review. Those in group 2 receive usual care. Pairs of students from the University of East Anglia are allocated 4 participants from group 1 to review under supervision at the patient’s medical practice. Students discuss their findings with the participants GP. Six weeks later supervised face to face medicines related consultations with reviewed participants are carried out at the University. A questionnaire is sent to all participants from both groups six months after the interviews and the results between the two groups compared. Focus groups are then held again in order to learn from the process.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
School of Pharmacy, University of East Anglia (UK)
When is the study starting and how long is it expected to run for?
February 2011 to November 2012
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
Mr Rick Adams
richard.adams@uea.ac.uk
Contact information
Public
School of Pharmacy, University of East Anglia
Earlham Road
Norwich
Norfolk
NR4 7TJ
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised; Interventional; Design type: Process of Care |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Supervised pharmacy student led medication review of patients with diabetes in primary care:a pilot study to ascertain the potential costs and effects. |
| Study objectives | Pilot study to identify if there are any benefits to type 2 diabetes patients in undertaking a student led medication review. In addition we will establish if there are any benefits in terms of education for the student. |
| Ethics approval(s) | 10/H0306/77 |
| Health condition(s) or problem(s) studied | Topic: Primary Care; Subtopic: Other Primary Care; Disease: All Diseases |
| Intervention | 1. Each intervention arm patient received a medication review of their medication by a student pharmacist, using their medical records. Any potential action forwarded to the patient's GP. Each intervention arm patient then met a student pharmacist for a one to one medication review. 2. Control patients received usual care. Follow Up Length: 3 month(s); Study Entry : Single Randomisation only |
| Intervention type | Other |
| Primary outcome measure(s) |
HbA1c; Timepoint(s): Pre intervention and 6 months post intervention |
| Key secondary outcome measure(s) |
1. Blood pressure; Timepoint(s): Pre intervention and 6 months post intervention |
| Completion date | 30/11/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 160 |
| Key inclusion criteria | 1. Prescribed non insulin medication for type 2 diabetes for at least 2 years 2. Willing to give consent 3. Registered with one of the 4 participating GP practices |
| Key exclusion criteria | 1. Deemed unsuitable for inclusion in the study for any reason by their GP 2. Enrolled in other clinical trials 3. Suffering from terminal illness |
| Date of first enrolment | 14/02/2011 |
| Date of final enrolment | 30/11/2012 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Norwich
Norfolk
NR4 7TJ
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 04/11/2015 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
01/09/2016: Publication reference added.
